MUSMedical University of South Carolina · Biochemistry
The RAS Targeting Initiative
John P O'Bryan · Charleston, South Carolina
Research Focus
Dr. John P. O'Bryan's lab focuses on understanding how certain proteins, called RAS, contribute to cancer development. They are exploring new ways to inhibit these proteins using innovative synthetic molecules called monobodies, which can bind to RAS with high specificity. By studying how these molecules affect RAS function, the lab aims to identify new strategies for cancer therapy that directly target RAS mutations.
RASmonobody inhibitorscancer therapyoncogenic mutationsprotein engineering
Research Aims
3AIM 01Utilize monobodies to investigate RAS biology and mechanisms of effector activation.
AIM 02Establish cell lines and mouse models to study the effects of RAS inhibition on tumorigenesis.
AIM 03Develop new monobodies targeting specific RAS mutants for therapeutic applications.
Skills the Lab Values
protein engineeringcell culturemouse modelsbiochemical assaysmolecular cloning
Output against the department
Publications122bottom 33% of dept.267th of 402
this lab
most publishedleast published
Citations5.2kbottom 30% of dept.280th of 402
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.